The Horizons Tracker

FEBRUARY 22, 2022

It’s a market that is already worth $3.1 billion and is estimated to be worth $48 billion by 2026, with the Covid pandemic driving growth, especially in the healthcare and pharmaceutical industries, but also in sectors such as automotive and defense. “ There are cases with upload speeds of over 1Gbps.

Stephenson 91

Stephenson Wireless Christensen Automotive 91

Lead on Purpose

SEPTEMBER 8, 2009

Over 150 companies, including Durkee, Cremora, San Giorgio, Ronzoni, and McCormick, now use the entire line of Flapper products, and Weatherchem continues to lead the industry in offering the widest, most innovative array of closure products. Filed under: Integrity , Leadership , Purpose , Team Building , Trust Tagged: | Albert J.

Committee 140

Committee Automotive Ethics Productivity 140

Harvard Business Review

AUGUST 3, 2016

That can benefit consumers through lower prices, more innovation, and better products. On the other hand, M&As can also strengthen the market power of the combined entity, reducing competition in a way that harms consumers. Research has shown that pharma mergers reduce innovation. What’s the reason for this?

Innovation 8

Innovation Pharmaceuticals Company Price 8

Strategy Driven

JULY 13, 2011

Since the unit’s reported financial results were so good, the executives at the corporate headquarters didn’t ask many questions about the drivers of the unit’s profits – until it was too late. It turned out that the unit was driving profits by raising prices and cutting marketing and advertising expenditures.

ROIC 62

ROIC Balanced Scorecard Metrics McKinsey 62

Harvard Business Review

FEBRUARY 16, 2017

Most businesses wouldn’t survive without driving demand for their products or services, either through marketing and advertising or through involving users so deeply in the design of the product that word of mouth spurs adoption. The same is true for social innovators. But even the most needed innovation does not sell itself.

Innovation 9

Innovation Rogers NGO Participative 9

Harvard Business Review

SEPTEMBER 23, 2014

I often hear this question when I visit companies and speak about how to make an innovative idea less terrifying to high level executives. There are plenty of pundits arguing that big companies need to innovate, and pointing out that it is difficult to do so. Have you actually seen this done?”. The skepticism is warranted.

Innovation 11

Innovation P&L Short-term Company 11

Harvard Business Review

FEBRUARY 17, 2011

Venture capitalists are increasingly interested in emerging markets, and in working with local funds based in those markets (despite the fact that reverse innovation in venture capital seems counterintuitive). In contrast, emerging-market VCs such as Nadathur Holdings (established in 2000 by N.S.

Marketing 15

Marketing Venture Capitalist Biotechnology IPO 15

Coaching Tip

MARCH 15, 2011

Nothing has ever been able to keep it down for long, and nothing ever will, if we are patient and allow our economy the time to heal itself through the virtues of the free-market system. . All it takes is the desire to be innovative and creative in tackling a problem. Deregulation. Entrepreneurship. Ask: How can we improve this place?

Pharmaceuticals 84

Pharmaceuticals Creativity Long-term Power 84

Harvard Business Review

JANUARY 27, 2016

Much fanfare has been paid to the term “disruptive innovation” over the past few years. Disruptive innovations are: Cheaper (from a customer perspective). Historically, the place we’ve looked for hints of oncoming disruptions has been in the low end of the market. Professor Clayton M. Is Uber disruptive?

Disruptive Innovation 8

Disruptive Innovation Innovation Short-term Long-term 8

Harvard Business Review

APRIL 19, 2016

Imagine the changes afoot in the pharmaceutical, medical device, automotive, and consumer electronics industries. Innovation, customization, speed, and location are also among the opportunities it offers. What would be the cost/benefit of flattening your supply chain and moving production closer to your markets?

Supply Chain 8

Supply Chain Execution Analysis Technology 8

Harvard Business Review

JUNE 13, 2016

No matter how you look at it, there have been terrible, unintended outcomes from the introduction and marketing of next-generation prescription opioids. Since 1999, three years after OxyContin was unveiled by Purdue Pharmaceuticals, the rate of drug overdoses in the U.S. And what can we learn from it?

Incentives 8

Incentives Pharmaceuticals Crisis P&L 8

Harvard Business Review

MARCH 28, 2012

The Swiss pharmaceutical giant Roche is nothing if not determined in its quest to acquire Illumina, the San Diego-based leader in genetic-sequencing equipment. An acquirer looking for innovation would have been likelier to try to buy Gateway, a company that is almost an after-thought now. billion tender offer directly to shareholders.

Innovation 13

Innovation Company Biotechnology CFO 13

Harvard Business Review

SEPTEMBER 14, 2011

We recently visited the brand-new R&D lab of Dr Reddy's , one of India's leading pharmaceutical firms. Dr Reddy's plan is to leverage Chirotech's scientific capabilities to optimize drug development processes, thus lowering manufacturing costs and speeding time-to-market. Cambridge, U.K. facility in Cambridge Science Park.

Globalization 10

Globalization Innovation Decentralization Chemicals 10

Harvard Business Review

OCTOBER 6, 2016

In a Deloitte study of 7,000 organizations this year, 89% of executives rated “ strengthening the leadership pipeline ” an urgent issue. So they’re looking for ways to cultivate those competencies and, in the process, feeding the fad-driven leadership development market. Insight Center. Sponsored by Korn Ferry.

Leadership Pipeline 13

Leadership Pipeline Leadership After Action Review Pharmaceuticals 13

Harvard Business Review

AUGUST 14, 2018

However, they have all failed in China, the world’s largest digital market. Google, for example, has succeeded in dominating many foreign markets that have radically different political systems and cultures (including Indonesia, Thailand, and Saudi Arabia). market on China. market on China.

Competitive Advantage 11

Competitive Advantage Business Model Technology Marketing 11

Harvard Business Review

SEPTEMBER 12, 2012

Business executives may not know it, but they are wasting billions of their gross profits on ineffective, even harmful drugs in their health plans. But while they are waiting for the next big breakthrough, companies have to fill their product line with clinically similar drugs to market as "better" than their competitors' similar drugs.

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

AUGUST 9, 2012

Selling pharmaceuticals in Latin America is not the same as selling them in the United States or Western Europe. Second, in most Latin American countries, pharmaceutical companies are not allowed to advertise directly to consumers. Right off the bat, I can identify four big differences. They were correct.

Pharmaceuticals 14

Pharmaceuticals Strategy Advertising Price 14

Harvard Business Review

MAY 7, 2015

This information improved marketing campaign targeting, as well as sales force targeting. In the pharmaceutical industry, technology is transforming the sales process. A few decades ago, pharmaceutical companies promoted their products almost entirely through personal contact by salespeople with physicians.

Trends 8

Trends Technology Pharmaceuticals Team 8

Strategy Driven

MARCH 18, 2011

In The Essential Advantage : How to Win with a Capabilities-Driven Strategy , Booz & Company’s Paul Leinwand and Cesare Mainardi maintain that success in any market accrues to firms with a coherence premium – a tight match between their strategic direction and the capabilities that make them unique. Let’s go after it.”

Resources 51

Resources Industry System Strategy 51

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

JULY 16, 2013

Consider the pharmaceutical industry, the focus of a recent global survey my colleagues and I conducted. We asked nearly 200 life sciences executives about long-term trends that posed fundamental threats to their businesses and how management was dealing with them. Only, it''s not at all funny. Experience threats through war games.

Industry 8

Industry Pharmaceuticals Disruptive Innovation Strategic Planning 8

Harvard Business Review

MAY 8, 2013

Then, automation and the Web put senior executives in touch with their own front lines — and handed many MLMs their pink slips. Nearly 68% of these large-scale change and innovative efforts failed. These MLMs were alienated and felt senior executives had used them as tactical tools.

Middle Management 9

Middle Management Management Automotive Pharmaceuticals 9

Harvard Business Review

MARCH 2, 2012

As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. HBS welcomes 6,360 foreign nationals (64% of the total) to its executive education courses each year, enriching the experiences for Americans as well.

Competitive Advantage 13

Competitive Advantage Globalization Development Intellectual Capital 13

Harvard Business Review

OCTOBER 23, 2014

That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. Life science company executives need to be thinking about what business they want to be in. They’re also sharing risk. The positions are there for the taking. But not for long.

Health Care 8

Health Care Pharmaceuticals Information Technology Supply Chain 8

Harvard Business Review

SEPTEMBER 10, 2013

A good idea faces so many obstacles en route to market today that it''s a wonder we have any innovative products at all. Effective means of boosting innovation already exist, but not enough companies are making use of them. You know those baby sea turtles that get eaten by birds and crabs on their way from the nest to the water?

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

SEPTEMBER 10, 2013

A good idea faces so many obstacles en route to market today that it’s a wonder we have any innovative products at all. Effective means of boosting innovation already exist, but not enough companies are making use of them. It’s like that. It doesn’t have to be this way. You can see why: For decades in the U.S.,

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

OCTOBER 22, 2013

Innovation starts with new and novel ideas. When we surveyed over 300 global executives between 2008 and 2009, one of the primary concerns they expressed was their inability to compete long term without a solid innovation engine that can grow their top line. Finding ideas is never the problem — initially. Find Pivots.

Skills 8

Skills Power Six Sigma Disruptive Innovation 8

Harvard Business Review

JUNE 16, 2011

So it is with most breakthrough innovations and banner financial years. Investors grapple daily in an effort to figure out how to value companies whose accounting assets — things like land, capital, products, and licenses — don't adequately express their true market value. If ego and time allow, the list can be quite long.

Intangible Assets 15

Intangible Assets Analysis Pharmaceuticals Innovation 15

Harvard Business Review

OCTOBER 25, 2018

We focus on economic profit rather than revenue size, market share, or productivity growth because these other metrics risk including firms that are simply large and may not create economic value. (To do this, we take the firm’s returns, deduct the cost of capital, and multiply by the firm’s total invested capital.)

Industry 13

Industry Company GDP Bottom-up 13

Harvard Business Review

SEPTEMBER 7, 2015

And the corporate executive playing games to improve his or her strategy-making skills is still rare. We think that games have an important place in cultivating good strategists, and that now more than ever games can give executives an edge over their competition. This is unfortunate. Games provide inexpensive, real-time feedback.

Seminar 8

Seminar Learning Curve Strategy Comparison 8

Harvard Business Review

DECEMBER 5, 2016

Library leaders knew that given the immense changes brought on by digital innovations, as well as shifts in the communities that the Library served, it would need to evolve. Involving staff in conceiving, designing, and implementing the change would result in a course of action that was more fit-to-purpose and more likely to be well executed.

Library 8

Library Strategy Reference Bottom-up 8

Harvard Business Review

SEPTEMBER 20, 2013

Content Innovation. Fortunately, the organizations that took the effort to truly understand the value of their data were able to execute appropriately. How do you ensure that your execution is commensurate with the revenue opportunity? In some cases, they’re right. But then again, in a surprising number of cases, they aren’t.

Execution 8

Execution Metrics Content Christensen 8

Harvard Business Review

DECEMBER 14, 2015

It’s no surprise, then, that the popularity of meditation – one way to practice mindfulness – is also growing among CEOs and senior executives. They want to see how these approaches … are truly beneficial to existing priorities like retention, talent advancement, innovation.” ” You and Your Team.

CEO 8

CEO Emotional Intelligence Cooper Pharmaceuticals 8

Harvard Business Review

OCTOBER 24, 2017

These have forced AirBnB, Tesla, and Uber to make costly concessions to their operating practices or to exit certain markets altogether. In industries being disrupted by new entrants with distinct business models, incumbents often have an important advantage: entrenched regulatory and legal barriers. In the U.S.,

Licensing 10

Licensing Proposal Retail Long-term 10

Strategy Driven

JANUARY 24, 2011

StrategyDriven effective executives, efficient employees Home About The StrategyDriven Organization Our Company Our Contributors Karen K. It’s that time of year again: time for business owners and senior executives to take stock of the past twelve months. Juliano Howard T. Dickens Jr. Ives Sharon Drew Morgen Hank Moore Jamie P.

Execution 67

Execution Company 360-Degree Feedback Cooper 67

Harvard Business Review

JANUARY 30, 2014

Second, wellness has become a marketing tool for health plans, nowhere more so than at Aetna. By cutting spending on failed wellness conventions, organizations will find room in the budget for wellness innovations that will raise morale by doing things for employees instead of to them. Revamping Wellness Programs.

Human Resources 10

Human Resources Guidelines Morale Insurance 10

Harvard Business Review

MAY 16, 2011

True collaboration always has open-ended elements — ranging from precisely how new innovations will be implemented, to how products will fare in the market, and even to what priorities partners will pursue in the face of changes in the environment. This landscape is evolving rapidly, in ways not even Google could foresee.

Software 15

Software Licensing Long-term Telecommunications 15